Contract awarded to the first and only FDA-authorized technology that objectively monitors a patient’s physiological response to pain during general anesthesia.
Medasense Biometrics has announced that its PMD-200™ pain response (nociception) monitoring system with NOL technology has received an Innovative Technology contract from Vizient®, the largest provider-driven healthcare performance improvement company in the U.S.
The Innovative Technology contract was awarded following review of the PMD-200 by hospital experts serving on one of Vizient’s client-led councils. It signifies to Vizient clients the technology’s unique qualities and recognizes the technology’s potential to improve healthcare delivery and bring real innovation to patient care.
